Telesis Bio, Inc. (TBIO)

3,6500 -0,3300 (-8,29%) Al cierre: 04:00PM EDT

Telesis Bio, Inc.

10431 Wateridge Circle
Suite 150
San Diego, CA 92121-2993
United States
858 228 4115
https://telesisbio.com

Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 127

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Eric Esser	President, CEO, COO & Director	429,11k	N/A	1969
Dr. Todd R. Nelson MBA, Ph.D.	Founder & Director	621,61k	N/A	1967
Mr. Robert H. Cutler	Chief Legal Officer	413,34k	N/A	1968
Mr. William J. Kullback	Chief Financial Officer	N/A	N/A	1960
Mr. Daniel G. Gibson Ph.D.	Chief Technology Officer	590,37k	N/A	1977
Ms. Jen Carroll	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Decky Goodrich M.B.A.	Senior Vice President of Corporate Development	N/A	N/A	N/A
Richard Lepke	Director of Investor Relations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de Telesis Bio, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.